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Objective: To evaluate the cost-utility of the treatment with a long acting beta-agonist (LABA)
and inhaled corticosteroid (ICS) combination inhaler [salmeterol xinafoate (SAL)/fluticasone
propionate (FP) combination inhaler (SFC) (Advair)] to continuing on current ICS dose (no
ICS dose change) or increased ICS dose [fluticasone propionate (FP)] in patients with uncon-
trolled asthma in Canada.
Methods: A cost-utility analysis was conducted from a Canadian public healthcare perspective
with a one year time horizon. In the no FP dose change scenarios, remaining on daily low (FP
100 ug BID) or medium (FP 200e250 ug BID) or high dose (FP 500 ug BID) was considered. In the
increased FP dose scenarios, doubling the FP dose from low to medium dose and from medium
to high dose regimens were considered. A decision model was developed with two health
states: “symptom free” or “with symptoms”. Clinical efficacy was based on a meta-analysis
of relevant randomized controlled trials. Over the one year time horizon the percentage with
symptom free days (SFD) was used as the measure of differential treatment scenario effective-
ness. Drug costs and non-drug costs were incorporated into the analysis. Utilities, derived from
EQ5D scores and health services resource use based on patient diaries for ‘symptom free’ and
‘with symptoms’ were based on regression analyses of individual patient data from the Gaining
Optimal Asthma controL (GOAL) trial. Costs were assessed by assigning unit cost for eachline Canada, 7333 Mississauga Rd, Mississauga, ON L5N 6L4, Canada. Tel.: þ1 905 814 3556; fax: þ1
.com (A.S. Ismaila).
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Salmeterol/fluticasone cost-effectiveness in asthma 1293health services resource use for each patient. The incremental cost-utility ratios (ICUR) for SFC
vs no FP dose change or increased FP dose were estimated using descriptive statistics. Uncer-
tainty was assessed by deterministic and probabilistic sensitivity analysis (PSA).
Results: Over one year, SFC resulted in an incremental cost per patient of $544e$655
compared to no FP dose change and $47e$380 per year compared to increased FP dose. SFC
results in incremental QALYs per patient of 0.0100e0.0149 compared to no FP dose change
and 0.0136e0.0152 compared to increased FP dose. The one year ICURs were $43,000 to
$54,400 per QALY gained for SFC compared to no FP dose change and $25,000 to $3500 per
QALY gained compared to increased FP dose scenarios. The probability of SFC being cost-
effective at $50,000 per QALY gained was greater than 75% compared to increased FP dose sce-
narios and compared to no dose change for patients on low or medium dose FP. The results
were robust to changes in assumptions within the model.
Conclusion: In Canadian patients with inadequately controlled asthma on FP, it is cost-
effective to use SFC for patients 12 years and over compared to doubling their FP dose. It is
also cost-effective to use SFC for patients on low or medium dose FP compared to remaining
on the current FP dose in patients with uncontrolled asthma.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Asthma is one of the most common chronic diseases
worldwide. In Canada, 2.4 million people aged 12 years or
older reported an asthma diagnosis in 2012 [1,2]. Canadian
and European health surveys showed that about 53% of
asthma patients have difficulty gaining and keeping optimal
control of their disease [3e5]. Poor asthma control restricts
a patient’s ability to participate in normal daily activities
and negatively affects quality of life. [6e8] Patients with
uncontrolled asthma also use significantly more health care
resources compared to patients with controlled asthma,
including urgent office visits, emergency room (ER) visits,
and hospitalizations [4,7,9,10].
For adults and adolescents whose asthma is uncontrolled
on a low dose of inhaled corticosteroid (ICS) alone, treat-
ment guidelines recommend adding a long acting beta2-
agonist (LABA); for children whose asthma is uncontrolled
on a low dose of ICS, physician can increase to a medium
dose of ICS, and then further add a LABA if asthma con-
tinues to be uncontrolled [11e14]. Before escalating the
treatment, physicians need to conduct a thorough review of
adherence to treatment with ICS, environmental factors,
co-morbidities and inhaler device technique [12,13]. Sys-
tematic reviews have shown that compared to treatment
with higher dose of ICS, a LABA/ICS combination is more
effective in preventing exacerbations, improving lung
function, and reducing symptoms and rescue medication
use with similar rates of adverse events [15,16].
A few published economic evaluations have shown that
LABA/ICS combination is cost-effective or dominant (less
costly and more effective) compared to similar or higher
dose of ICS in the regimen in Europe [17e26] and the United
States [27]. However, limited studies are available in Can-
ada. The aim of this study was therefore to assess the cost-
utility of LABA/ICS versus ICS alone in Canadian patients
with uncontrolled asthma using a decision analytic model.
Costs, symptom free days and quality adjusted life years
(QALYS) were estimated over a one year timeframe.Methods
Overview
In patients with uncontrolled asthma on low, medium or
high dose fluticasone propionate (FP), a cost-utility analysis
was conducted to compare no FP dose change or a one step
increase in FP dose (i.e. low to medium daily dose increase)
to treatment with LABA/ICS. The analysis was done from a
Canadian public healthcare perspective and with a one year
time horizon. The decision model is a Canadian adaptation
of a United Kingdom perspective model developed by Doull
et al. [20]. The model has two heath states: “symptom
free” and “with symptoms”. The %SFD is a commonly used
effectiveness measure and used in many published cost-
effectiveness studies which compared LABA/ICS combina-
tion to ICS alone in patients with asthma [17,21,23e25,27].
Treatment effect was incorporated by the increment pro-
portion of time with “symptom free days” based on a meta-
analysis of randomized trials. Assigned to each health state
are measures of utility and costs based on individual patient
regression analysis from the Gaining Optimal Asthma con-
troL (GOAL) trial [28].Treatment comparisons
The treatment comparators in the analysis were based on
current Canadian treatment guidelines [12,13]. In Canada,
treatment with ICS is the standard of care for persistent
asthma and FP is the most commonly used ICS. The ICC/
LABA combination inhaler (salmeterol xinafoate/flutica-
sone propionate (SFC) is commonly used and currently
reimbursed in all Canadian provinces for the treatment of
asthma in patients who experience ongoing symptoms
despite using anti-inflammatory therapy (i.e. ICS)). Thus,
the study focused on the comparison of SFC (Advair) to FP.
SFC was compared to no FP dose change or one step in-
crease in FP dose per day as described in Table 1.
Table 1 Comparisons of SFC against the same or
increased FP daily dose.
Intervention:
SFC
Comparator:
same dose FP
Comparator:
increased dose FP
SFC200 FP200 FP400e500
SFC500 FP400e500 FP1000
SFC1000 FP1000 Not applicable
Abbreviations: FPZ fluticasone propionate; FP200Z 200 mg FP
per day; FP400e500 Z 400e500 mg FP per day;
FP1000 Z 1000 mg FP per day; SAL Z salmeterol xinafoate;
SFCZ SAL/FP combination; SFC200Z 100 mg SAL/200 mg FP per
day; SFC500Z 100 mg SAL/500 mg FP per day; SFC1000Z 100 mg
SAL/1000 mg FP per day.
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To determine the costs and utility weights for each health
state, ‘symptom free’ and ‘with symptoms’ a regression
analysis was conducted based on patient outcomes cate-
gorized by week of “symptom free” and “with symptoms”
based on a patient level analysis of the GOAL trial
[19,20,28].
The GOAL study was a 12 month, multinational, ran-
domized, stratified, double-blind, parallel-group study of
3416 patients with uncontrolled asthma comparing step-
wise increases of SFC with FP alone to achieve two pre-
defined composite measures of asthma control. Patients
were divided into three strata based on their daily use of
ICS in the 6 months prior to study entry: Stratum 1, no prior
ICS; stratum 2, 500 mg or less per day of beclometasone
dipropionate (BDP), chlorofluorocarbons (CFC) or equiva-
lent (equivalent to 250 mg or less of FP); or stratum 3,
>500e1000 mg or less of BDP CFC or equivalent (equivalentTable 2 Baseline characteristic of GOAL study population.
Strata Stratum 2
Inhaled corticosteroid use in previous
6 months to trial enrollment
500 mg BDP or e
SFC vs FP
n 585
Mean age, yr (SD) 40.4 (16.4)
Age range 12e78
Sex, % female 58
Atopy, % 60
Mean prebronchodilator FEV1, L (SD) 2.4 (0.83)
% Predicted (SD) 78 (18.2)
Mean morning PEF, L/min (SD) 345 (98.7)
% Predicted (SD) 78 (16.1)
Reversibility,a median % (interquartile range) 22 (13.4)
Rescue medication, mean occasions/day, (SD) 1.7 (1.5)
Mean daily symptom score,b (SD) 1.8 (0.9)
Night time awakenings, mean occasions/night 0.4 (0.6)
Exacerbation ratec (SD) 0.6 (1.3)
Abbreviations: BDP Z beclomethasone dipropionate; FP Z fluticason
a Reversibility for those patients in whom it was measured during r
b Symptom score: 0 (none)e5 (severe).
c Documented episodes of hospitalization and/or course of oral ster
during the past 12 months.to 500 mg or less of FP). In Canada, as a LABA/ICS combi-
nation is given only to patients whose asthma is not
adequately controlled on an ICS alone, the ICS naı¨ve pa-
tients (Stratum 1) was not relevant to Canada and thus,
excluded from our analysis. Patients entering the model are
assumed to be similar in characteristic to those enrolled in
the GOAL study with prior ICS exposure (Stratum 2 and 3)
(Table 2).
In the GOAL trial, weekly, patients were classified into
one of the four mutually exclusive asthma control states
based on level of control: “totally-controlled” (TC), “well-
controlled” (WC), “not well-controlled but without exac-
erbation” (NWC), and “exacerbations” (X). The definitions
of TC or WC were based on the GINA guidelines and were
composite measures of daytime symptoms, rescue medi-
cation use, morning PEF, night time awakenings, exacer-
bations, emergency department visits, and adverse events
(Table 3). For patients not achieving either TC or WC in a
given week, their asthma control state was classified as
either NWC or X based on whether or not they had an
exacerbation. An exacerbation was defined as deterioration
in asthma requiring treatment with an oral corticosteroid,
or an emergency department visit or hospitalization
[19,20,28]. For the current economic analysis, patients in
the TC state were regarded as being in the “symptom free”
health state, and patients in the other three states were
weighted together as the “with symptoms” health state.
Utility and non-drug cost of the “with symptoms” state
therefore represents a patient-week weighted average
across WC, NWC and X states. [19]
Estimate of costs
The non-drug costs associated with the “with symptoms”
and “symptom free” health states were estimated fromStratum 3
quivalent daily >500 to 1000 mg BDP or equivalent daily
SFC vs FP
578 576 579
40.3 (16.6) 44.1 (15.9) 42.7 (15.7)
9e80 12e83 12e80
60 57 59
58 63 58
2.4 (0.80) 2.3 (0.82) 2.3 (0.79)
77 (18.4) 75 (18.6) 76 (17.6)
348 (96.3) 345 (98.7) 348 (96.3)
78 (16.3) 78 (16.0) 79 (16.2)
22 (13.3) 23 (12.8) 22 (12.8)
1.7 (1.4) 1.9 (1.5) 1.9 (1.4)
1.8 (0.9) 1.9 (0.9) 1.9 (0.9)
0.4 (0.5) 0.5 (0.6) 0.5 (0.6)
0.5 (1.0) 0.7 (1.2) 0.7 (1.5)
e propionate; SFC Z salmeterol/fluticasone combination.
un-in.
oids or antibiotics for the treatment of an exacerbation of asthma
Table 3 Definitions of model health states and asthma control states based on Global Initiative for Asthma (GINA) guidelines.
Model health states “Symptom free” “With symptoms”
GOAL trial control states Totally controlled
(TC)
Well-controlled (WC) Not well-controlled
but without
exacerbation (NWC)
Exacerbation (X)
Each week all of: Each week 2 or more of: Not achieving either
TC or WC in a given
week but with no
exacerbation
Having
exacerbation
Daytime symptoms None 2 days with symptom score >1
Rescue b2-agonist use None Use on 2 days and 4 occasions
per week
Morning PEF 80% Predicted every
day
80% Predicted every day
Night time awakening None None
Exacerbations None None
Emergency visits None None
Treatment-related
adverse events
None enforcing
change in asthma
therapy
None enforcing change in asthma
therapy
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collected in the GOAL trial [19,28] and the method is
described in the section below. The healthcare resources
included hospitalizations (ICU and general ward), ED visits,
outpatient visits, physician contacts, and rescue medica-
tions. The GOAL regression analysis was re-run with Cana-
dian unit costs to generate Canadian-specific estimates for
non-drug costs.
Canadian unit costs of healthcare resource use were
obtained from the Ontario Schedule of Benefits [29],
Ontario Drug Benefit Formulary [30], and Alberta Case
Costing Report [31]. Costs were reported in 2011 Canadian
dollars. All cost inputs are summarized in Table 4. The drug
costs were calculated assuming 100% adherence. Flutica-
sone propionate (FP) is the most commonly used ICS
treatment in Canada, thus was used as the ICS comparator.
Salmeterol xinafoate/fluticasone propionate was the LABA/
ICS combination inhaler (SFC) (Advair) comparator used in
the analysis.
Costs per day in either an intensive care unit (ICU) or
general ward bed for asthma-related hospitalizations were
not available in Canada. Therefore these costs were
derived utilizing the method by Miller et al. [32]. Asthma-
related hospitalization costs (Case Mix Group 146) were
obtained from the 2006/2007 Alberta Case Cost Report [31]:
ICU costs were assigned the average cost per day at the
level of complexity identified as Plx 4 e potentially life-
threatening condition ($1734.50), and general ward costs
were assigned the average cost per day at the level of
complexity identified as Plx 1 e no complication ($1421).
Ambulatory care costs were also obtained from the 2006/
2007 Alberta Case Cost Report [31]: the cost of an ED visit
was assigned the cost of managing severe respiratory dis-
ease (ACCS 864, $265), and the cost of an outpatient visit
was assigned the cost of managing general respiratory dis-
ease (Ambulatory Care Classification System [ACCS] 856/
857, $182). The hospitalization and ambulatory care costswere then inflated to 2011 currency using the health care
component of the Canadian Consumer Price Index [33] and
a daily physician visit cost was added: $38.05 for ICU and
general ward (Respiratory medicine partial assessment
A478), $35.40 for an ED visit (Emergency department par-
tial assessment A888), and $38.05 for outpatient visit
(Respiratory medicine partial assessment A478).
The Alberta hospitalization costs were chosen as inputs
for the base case analysis because the costs were available
by severity to derive the approximate the ICU and general
ward costs.
The results of the non-drug cost regression analysis per
patient by health state are presented in Table 5. The
weekly cost of disease management for a ‘symptom free’
week, was significantly lower ($0.885) than the cost in
patients ‘with symptoms’ ($5.44). These weekly costs, in
addition to drug costs were applied the two health states in
the model.Estimation of utilities
Health state utility weights were assigned independently to
each of the two health states. European Quality of Life 5
Dimensions (EQ5D) utility scores were derived from the
Asthma Quality of Life Questionnaire (AQLQ) data collected
in the GOAL trial using a mapping algorithm from an
external study in which both EQ5D utility scores and AQLQ
data were collected [19,20]. Linear regression analysis was
undertaken to compare the average utility value during
time “symptom free” compared to “with symptoms” and
adjusted to generate Canadian-specific utility estimates.
This was conducted by including a Canada indicator vari-
able to adjust for differences in utility between Canada and
other countries found in the GOAL analysis.
The results of the GOAL study utility regression analysis
by health state are presented in Table 5. The ‘symptom
Table 4 Unit costs (2011 CAD$).
Input Base case Source
Annual drug cost (assume 100% adherence) 2011 Ontario Drug Benefit Formulary [30]
SFC200 $975.65
SFC500 $1167.88
SFC1000 $1657.95
FP200 $291.14
FP400e500 $564.79
FP1000 $1094.63
Asthma-related resource use
Intensive care unit cost per daya $2035.18 Alberta Case Cost Report (CMG146-plx4) [31];
Ontario Schedule of Benefits (A478) [29]
General ward cost per daya $1647.21 Alberta Case Cost Report (CMG146-plx1) [31];
Ontario Schedule of Benefits (A478) [29]
Cost per emergency room visita $340.52 Alberta Case Cost Report (ACCS864) [31];
Ontario Schedule of Benefits (A888) [29]
Cost per outpatient visita $247.61 Alberta Case Cost Report (ACCS856/857) [31];
Ontario Schedule of Benefits (A478) [29]
Cost per daytime home visit $45.15 Ontario Schedule of Benefit (A901) [29]
Cost per night time home visit $45.15 Ontario Schedule of Benefit (A901) [29]
Cost per general practitioner office visit $45.90 Ontario Schedule of Benefit (A006) [29]
Cost per telephone contact $45.15 Assume the same as a home visit
Each use of rescue medication $0.06 Ontario Drug Benefit Formulary [30]
(2 puffs of salbutamol)
Abbreviations: FP200Z 200 mg FP per day; FP400e500Z 400e500 mg FP per day; FP1000Z 1000 mg FP per day; SFC200Z 100 mg SAL/
200 mg FP per day; SFC500 Z 100 mg SAL/500 mg FP per day; SFC1000 Z 100 mg SAL/1000 mg FP per day.
a Physician fee per day included.
1296 A.S. Ismaila et al.free’ utility score, was significantly higher (by þ0.121) than
the utility score ‘with symptoms’ (0.809), indicating
significantly better quality of life in patients without
symptoms The adjusted utility scores for the Canadian
population were applied to the time ‘symptom free’ and
‘with symptoms’ health states (0.948 and 0.827, respec-
tively) in the model.
Efficacy
The differential treatment effects were measured by the
percentage change of time with symptomfree days (%SFD)
per week from baseline to follow-up. Treatment effects
were obtained from the Doull et al. study, which conducted
a meta-analysis of randomized controlled trials comparing
SFC against FP published as of 2006 [20] (Table 6).Table 5 Utility and weekly non-drug costs for each health stat
Utility regression
parameters
Utility of
state (SE)
Utility (SE) p value
Symptom free 0.121 (0.005) <0.001 0.948 (0.0
With symptoms
(constant)
0.809 (0.004) 0.113 0.827 (0.0
Canada 0.018 (0.012) <0.001
Abbreviation: SE Z standard error.The inclusion criteria for the meta-analysis were:
- Randomized controlled trial design
- Included adult patients (over the age of 12) with un-
controlled persistent asthma
- Reported %SFD data with standard deviation, standard
error or percentiles
- Compared a fixed dose of SFC with BID dosing to the
same or increased dose of FP alone, excluding step-down
dosing designs
- Published in English
A literature search was conducted in October 2011 to
identify any new studies fulfilling the meta-analysis inclu-
sion criteria after 2006. Nine studies were identified
comparing SFC to FP but none met the inclusion criteria fore.
each Cost regression
parameters
Weekly cost of
each state
(CAD$)
(SE)
Cost p value
04) 4.555 (1.222) <0.001 0.885 (1.694)
04) 5.440 (1.449) <0.001 5.440 (1.449)
Table 6 Efficacy inputs generated from the Doull et al. meta-analysis (adults and adolescents over 12) [20].
Comparison Study Incr. %SFD SE 95% LCI 95% UCI
SFC vs no change in FP dose
SFC200 FP200 SAM40027 [28] 11.70 2.21 7.36 16.04
SFCB3022(25/50 treatment arm) [46] 13.20 3.88 5.59 20.81
SFCB3022(50/100 treatment arm) [46] 13.20 3.84 5.67 20.73
WMD Fixed effects 12.29 1.72 8.92 15.66
SFC400-500 FP400e500 SAM40027 [28] 10.10 2.17 5.84 14.36
SAS30004 [47] 12.90 5.89 1.35 24.45
SFCA3003 [48] 16.00 6.19 3.88 28.12
WMD Fixed effects 10.98 1.94 7.18 14.78
SFC1000 FP1000 SFCB3019 [49] 9.80 4.12 1.72 17.88
SFCB3023(25/250 treatment arm) [50] 10.90 4.19 2.70 19.10
SFCB3023(50/500 treatment arm) [50] 4.60 4.22 3.68 12.88
WMD Fixed effects 8.47 2.41 3.74 13.20
SFC vs increased dose FP
SFC200 FP400e500 SAM30013 [51] 12.98 6.45 0.34 25.62
SFC400-500 FP1000 SAS40009 [52] 11.00 4.19 2.79 19.21
Abbreviations: Incr. Z incremental; SFD Z symptom free days; SE Z standard error, LCI Z lower confidence interval; UCI Z upper
confidence interval; WMD Z Weighted Mean Difference; FP200 Z 200 mg FP per day; FP400e500 Z 400e500 mg FP per day;
FP1000Z 1000 mg FP per day; SFC200Z 100 mg SAL/200 mg FP per day; SFC500Z 100 mg SAL/500 mg FP per day; SFC1000Z 100 mg SAL/
1000 mg FP per day.
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[34] used a step-down dosing design and SFC was once daily
administration; Chuchalin et al. [35] used SFC once daily
administration; De Blic et al. [36], Gappa et al. [37],
Lemanske et al. [38], Vaessen-Verberne et al. [39] and
Murray et al. [40] were studies of children less than 12 years
of age; Clearie et al. [41] was a study of smokers with
asthma which is also not the population of interest; and
Koenig et al. [42] was excluded as it employed a flexible
dosing schedule. Therefore, no update to the meta-analysis
was warranted.
Analyses
Base Case analyses
Incremental costs and QALYs of SFC versus the no FP dose
change or increased FP dose were calculated over the one
year timeframe for all patients. The incremental cost
included both drug and non-drug costs. The incremental
non-drug cost was calculated by multiplying the number of
SFD gained with the cost saving per day of being “symptom
free” compared to “with symptoms”. Similarly, the QALY
gained was calculated by multiplying the number of SFD
gained with the utility improvement per day of being
“symptom free” compared to “with symptoms”.Table 7 Ontario Cost Costing Initiative asthma hospitalization
Age # cases Length of stay (days)
Mean SD
18e69 724 3.7 3.4
70þ 265 5.7 5.6
Weight cost/day for 18 years of age or over (2010 CAD$)
Abbreviation: SD Z standard deviation.The Base Case results were generated probabilistically
using Monte Carlo simulation with 1000 iterations. The
mean treatment effects were sampled from a normal dis-
tribution. The other non-drug cost and utility regression
coefficients were estimated from a multivariate normal
distribution. Treatment costs were regarded as fixed.
Deterministic sensitivity analyses
To examine the robustness of our findings to individual
model parameters, a number of one-way deterministic
sensitivity analyses were performed. Efficacy, utility and
non-drug cost were varied using the upper and lower
boundary of the 95% confidence interval.
One scenario analysis was performed using hospitaliza-
tion cost from an alternative Canadian province (Ontario)
instead of Alberta to test the effect of asthma-related
hospitalization costs on the overall cost-effectiveness. The
Ontario Case Costing Initiatives (OCCI) database [43] re-
ported asthma hospitalization to be $1107 per day and did
not break it down by ICU or general ward. It was viewed by
clinical experts to be lower than the expected cost for this
type of hospitalization. This cost was obtained from the
2010 OCCI inpatient database by selecting all cases (both
typical and atypical) of hospitalization with asthma as the
most responsible diagnosis (CMG 146) for individuals overcosts.
Total cost per case (2010 CAD$)
Mean SD Cost/day
$4112 $6515 $1111
$4789 $5090 $840
$1039
Table 8 Base case probabilistic cost-effectiveness results for SFC in adults and adolescents over 12 with uncontrolled asthma
(2011 CAD$).
Comparison Incr
drug
cost ($)
Incr
non-
drug
cost ($)
Incr
total
cost ($)
Incr
SFD
Incr
QALY
ICER
(Incr cost
/Incr
QALY)
Probability of
being cost-
effective
at $50,000/QALY
All patients
SFC vs same dose FP
SFC200 FP200 684.51 29.57 654.93 44.95 0.0149 43,981 77%
SFC500 FP400e500 603.08 26.68 576.40 40.55 0.0134 42,911 78%
SFC1000 FP1000 563.33 19.77 543.56 30.14 0.0100 54,411 39%
SFC vs increased dose FP
SFC200 FP400e500 410.85 30.45 380.40 46.09 0.0152 24,959 86%
SFC500 FP1000 73.25 26.73 46.52 40.94 0.0136 3432 99%
Abbreviations: Incr Z incremental; SFD Z symptom free days; QALY Z quality adjusted life years; ICER Z incremental cost-
effectiveness ratio; FP200 Z 200 mg FP per day; FP400e500 Z 400e500 mg FP per day; FP1000 Z 1000 mg FP per day;
SFC200 Z 100 mg SAL/200 mg FP per day; SFC500 Z 100 mg SAL/500 mg FP per day; SFC1000 Z 100 mg SAL/1000 mg FP per day.
1298 A.S. Ismaila et al.the age of 18. The average total cost per case and length of
stay were presented in Table 7. Cost per day of hospitali-
zation was calculated by dividing the average total cost per
case by the average length of stay. This cost included both
direct and indirect (hospital overhead) costs, but not
physician costs. The cost was then inflated to 2011 currency
using the health care component of the Canadian Consumer
Price Index [33], and then added the cost of one respiratory
medicine partial assessment per day ($38.05) for a total
cost of $1107 per day.
Results
Cost-effectiveness results
The Base Case incremental cost-effectiveness ratios (ICER)
per patient of SFC compared to no FP dose change or
increased FP dose are shown below for all patients based on
a probabilistic model analysis (Table 8). The probabilistic
results were similar to the deterministic results (not
presented).Table 9 One-way deterministic sensitivity analysis results ($/Q
Base
case
ICER
Efficacy
(change in %SFD)
Other costs e
symptom free
95% LCI 95% UCI 95% LCI 95% UC
Same dose FP
SFC200 FP200 43,981 61,452 34,165 42,826 45,289
SFC500 FP400e500 42,911 67,440 31,777 42,201 44,664
SFC1000 FP1000 54,411 122,426 33,330 51,781 54,244
Increased dose FP
SFC200 FP400e500 24,959 996,299 11,294 22,963 25,426
SFC500 FP1000 3,432 19,720 1,188 2,298 4,762
Abbreviations: Incr Z incremental; SFD Z symptom free days; Q
effectiveness ratio; FP200 Z 200 mg FP per day; FP400e500 Z
SFC200 Z 100 mg SAL/200 mg FP per day; SFC500 Z 100 mg SAL/500 mFor all patients, the results of the current study
demonstrated that SFC was more effective clinically than
both no FP dose change and increased FP dose with regard
to SFD gained (þ30.14e46.09 SFDs) and QALY gained
(þ0.0100e0.0152 QALYs) within one year. SFC was about
$550e$650 more expensive compared to same dose FP, and
only slightly more expensive per year compared to
increased dose FP ($46e$380). The resulting ICERs of SFC
versus no FP dose change were $43,981, $42,911, and
$54,411 per QALY gained for patients treated with the FP
comparator of low, medium and high FP doses, respec-
tively; and the ICERs of SFC versus increased FP dose were
$24,959 and $3432 per QALY gained for patients with FP
dose increased to FP 400e500 mg per day or FP dose
increased to 1000 mg per day, respectively (Table 8).Sensitivity analyses results
One-way deterministic sensitivity analysis results are pre-
sented in Table 9. Results were the most sensitive to effi-
cacy inputs, especially for the comparisons of SFC toALY).
Other costs e with
symptoms
Utility e symptom
free
Utility e with
symptom
I 95% LCI 95% UCI 95% LCI 95% UCI 95% LCI 95% UCI
45,111 43,055 51,729 38,159 38,458 52,404
44,485 42,429 50,995 37,618 37,913 51,660
54,065 52,009 62,241 45,913 46,273 63,052
25,247 23,192 28,413 20,960 21,124 28,784
4,583 2,527 4,156 3,066 3,090 4,211
ALY Z quality adjusted life years; ICER Z incremental cost-
400e500 mg FP per day; FP1000 Z 1000 mg FP per day;
g FP per day; SFC1000 Z 100 mg SAL/1000 mg FP per day.
Table 10 Studies that were included by the CADTH meta-analysis but did not meet the inclusion criteria of the current study.
Studies included in CADTH meta-analysis Reason excluded in current study
Busse et al. [53]; GSK SAS40036 2005 [51] ICS step down studies
Baraniuk et al. [54] Comparator not of interest (triamcinolone)
GSK SAM40120 2005 [51] Population not of interest (asthmatics with smoking history only)
Kavuru et al. [55] Included ICS naı¨ve patients for which SFC is not indicated in Canada
Ind et al. [56] (same study as GSK
SLGQ97/SLGB4010 2005 [51])
Lack of appropriate reporting of errors
Abbreviations: ICS Z inhaled corticosteroid; SFC Z salmeterol xinafoate/fluticasone propionate.
Salmeterol/fluticasone cost-effectiveness in asthma 1299increased dose of ICS. Utility inputs had a small impact on
the cost-effectiveness results. Results were not sensitive to
other costs inputs.
In the scenario analysis with Ontario hospitalization
cost, the ICERs were similar to the Base Case. The ICERs of
SFC versus same dose FP were $44,393, $43,767, and
$53,347 per QALY gained for low, medium and high doses,
respectively; and the ICERs of SFC versus increased dose FP
were $24,530 and $3865 per QALY gained for low and me-
dium doses, respectively.Discussion
The results of this economic analysis demonstrated that
treatment of uncontrolled persistent asthma with SFC is
cost-effective in Canada compared to both same and
increased dose FP.
The current study builds on previous publications in this
field in a number of ways. It reports results in cost per
QALY, whereas most of the other economic studies reported
results in cost per SFD [17,21,23e25,27] or cost per suc-
cessfully controlled (or treated) week [21e25]. This is in
accordance with the CADTH guidelines for economic eval-
uations; QALY is the preferred measure of outcomes
because of its clarity, simplicity, ease of application, and
face validity [44]. The result in cost per QALY is easier for
Canadian decision makers to interpret and judge if a drug is
cost-effective. Furthermore, clinical efficacy of the current
study is based on a meta-analysis of several randomized
controlled trials rather than a single trial as used by most
studies [17e19,21,23e26].
A few studies have been conducted comparing the cost-
effectiveness of LABA/ICS combination with similar or
higher dose of ICS in Europe [17e26] and the United States
[27]. Most studies used symptom free days, successfully
controlled weeks, or rescue free days as effectiveness
measures, and found LABA/ICS to be more costly and more
effective than a similar dose of ICS [17,21,22,24,25] or
higher dose of ICS [23]. LABA/ICS was found to be dominant
(less costly and more effective) in two studies [18,26]. Only
two British studies [19,20] incorporated quality adjusted
life years (QALY) outcomes and both found LABA/ICS to be
cost-effective compared to higher dose of ICS.
A Markov model based cost-utility analysis, conducted
by the Canadian Agency of Drug and Technologies in Health
(CADTH) compared four strategies of adding LABA to ICS:
when the patient is naı¨ve to ICS, or when asthma is un-
controlled on a low, medium or high dose of ICS [45]. The
patient cohort transitioned each week with adjustment indrug therapy (same dose, reduced dose, or increased dose)
and incidence of exacerbations (self-managed, general
practitioner or emergency department managed, or hospi-
talization). The analysis found that the most cost-effective
option was to add a LABA in the presence of inadequate
control on high dose ICS. This is not aligned with the GINA
[11], and Canadian Thoracic Society [12,13] guidelines that
recommend adding a LABA to a low dose ICS in adults and
adolescents with uncontrolled asthma.
The current study differs from the CADTH cost-utility
study in several ways. First, it does not explicitly deal with
treatment sequencing as per the CADTH study. Second,
utility estimates of the current study were based on the level
of symptom control whereas in the CADTH study were based
on exacerbations: asthma without exacerbations (0.78),
exacerbation without hospitalization (0.57), and exacerba-
tionwithhospitalization (0.33) [45]. Treatment effectiveness
on based on symptom free weeks was included but did not
link this outcome to quality of life measures. In the CADTH
report, since quality of lifemeasurewas based on rare events
such as exacerbation and hospitalization, the incremental
QALY gain is very small for all strategies at one year. There-
fore, the quality of life impact of symptom control was not
assessed in the CADTH analysis. The resulting ICERs are very
large (the ICER of adding a LABA to a medium dose of ICS
compared to adding a LABA to a high dose of ICS is about
190,000/QALY, and the ICER of adding a LABA to ICS naı¨ve
patients compared to a low dose of ICS is almost 4,000,000/
QALY), suggesting that the later LABA is introduced, themore
cost-effective the strategy. In our study, itwas not possible to
abstract comparable information on exacerbations across
trials. Exacerbations reflect only a small fraction of patients’
experience of asthma (1% of time in the GOAL study). The %
SFD ismore appropriate than rates of exacerbation in asthma
models because it directly reflects the patients’ experience
of persistent asthma and is widely reported in clinical
studies. Although a distinct exacerbation model health state
was not included in the present analysis, exacerbations were
considered and included in the “with symptoms” health state
(Table 1).
Lastly, the efficacy assessment in the current study was
a slightly different method than utilized by CADTH. In the
current study, he average % SFD “change from baseline over
12 weeks” was extracted or derived whereas CADTH did not
distinguish the difference between “change from baseline
over 12 weeks” or “change from baseline at week 12”.
Therefore, potentially a larger change from baseline would
be found using the CADTH method. The current study is
more conservative and the results better represent the
overall treatment effect.
1300 A.S. Ismaila et al.We also compared the studies included in the current
study with the CADTH meta-analysis and we excluded some
studies that were included in the CADTH meta-analysis
because they did not meet the inclusion criteria of our
study (Table 10).
There are a few limitations in our study. First, for the
comparison of SFC versus increased dose FP, there was a
lack of clinical trials that met the inclusion criteria for the
meta-analysis. Only one trial was included for each com-
parison. Second, EQ5D utility scores were not directly
available for each health state, and instead were translated
from AQLQ scores. It was assumed that the utility scores
mapped from the AQLQ are representative of those that
would have been obtained directly from patients in the two
asthma control states in GOAL using the EQ5D. Third, as this
model does not explicitly address treatment sequencing, it
does not directly answer the question as to whether LABAs
should be added after a low or high dose of ICS.
In addition, several assumptions have been made in
building the model for simplicity. It was assumed that there
is no difference in adverse events between treatments. For
costing of hospitalization, a daily physician visit was
assumed. However, according to clinical expert opinion, a
second respiratory consultation might be triggered if pa-
tients were admitted to the hospital by a generalist. As a
result, physician costs might be underestimated in the
model.Conclusions:
The results showed that SFC is very cost-effective
compared to increasing the dose of FP (ICERs are $25,000
and $3500 per QALY for FP400e500 ug per day and
FP1000 ug respectively) based on the generally accepted
Canadian cost-effectiveness threshold of $50,000 per QALY
gained. The results also demonstrated that SFC is cost-
effective compared to same dose FP as the ICERs are just
within the accepted threshold (approximately
$43,000e$54,400 per QALY). The results were robust to
changes in assumptions within the model.
Therefore, in Canadian patients with inadequately
controlled asthma on ICS, it is a cost-effective strategy to
add LABA in the form of LABA/ICS combination therapy
(SFC) for patients who remain uncontrolled on ICS
compared to doubling the dose of ICS. Utilizing ICS/LABA in
the form of SFC, is also a cost-effective strategy for pa-
tients uncontrolled on low or medium dose ICS compared to
remaining on the current ICS dose.Financial support
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